Skip to main
ARCT
ARCT logo

Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

Arcturus Therapeutics (ARCT) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 41%
Buy 32%
Hold 14%
Sell 5%
Strong Sell 9%

Bulls say

Arcturus Therapeutics Holdings Inc. has demonstrated considerable potential for growth, particularly with the recent approval of its COVID-19 vaccine Kostaive in the European Union, which validates its innovative self-amplifying mRNA platform. The company's collaboration with CSL Seqirus to handle commercialization efforts reduces execution risk, thus providing a robust operational foundation for launching its products. Additionally, projected revenues exceeding $500 million within five years of product launch, coupled with enhancements in manufacturing capabilities and a favorable clinical efficacy profile, contribute to a positive long-term outlook for Arcturus's stock.

Bears say

Arcturus Therapeutics Holdings Inc. has faced a substantial downward revision in its revenue estimates, particularly for its Kostaive product, with projections for the 2026 COVID season falling from $156.4 million to just $11.8 million due to significantly lower expected vaccination demand in Japan. The company reported a net loss of $30 million for 4Q24 and a negative earnings per share of $1.11, which raises concerns about its ongoing operational viability given its high cash burn rate and reliance on the success of its lead mRNA asset. Key risks include potential safety issues with its candidates, the efficacy of its drugs in clinical trials, and challenges in securing sufficient funding, all of which contribute to a negative outlook on the stock's performance.

Arcturus Therapeutics (ARCT) has been analyzed by 22 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 32% recommend Buy, 14% suggest Holding, 5% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcturus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcturus Therapeutics (ARCT) Forecast

Analysts have given Arcturus Therapeutics (ARCT) a Buy based on their latest research and market trends.

According to 22 analysts, Arcturus Therapeutics (ARCT) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.04, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.04, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcturus Therapeutics (ARCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.